B-RAF mutant cancer cell lines have been shown, as expected, to be highly responsive to MEK inhibition but not AKT inhibition, whereas KRAS-mutant cell lines show almost equal sensitivity to both MEK and AKT inhibition. This evidence concerns the gene KRAS and cancer.